NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR TRANEXAMIC ACID IN 0.7% SODIUM CHLORIDE INJECTION
Nexus Pharmaceuticals announced the FDA approval of Tranexamic Acid in 0.7% Sodium Chloride Injection, a new addition to their generic injectable portfolio. Tranexamic Acid in 0.7% Sodium Chloride is an intravenous antifibrinolytic indicated for short term use in hemophilia patients to promote healthy blood clotting following various procedures. “We are thrilled to be expanding our […]
Continue Reading